Abstract:Autotaxin (ATX) is a soluble extracellular enzyme that is abundant in mammalian plasma and cerebrospinal fluid (CSF). It has two known enzymatic activities, acting as both a phosphodiesterase and a phospholipase. The majority of its biological effects have been associated with its ability to liberate lysophosphatidic acid (LPA) from its substrate, lysophosphatidylcholine (LPC). LPA has diverse pleiotropic effects in the central nervous system (CNS) and other tissues via the activation of a family of six cognate G protein-coupled receptors. These LPA receptors (LPARs) are expressed in some combination in all known cell types in the CNS where they mediate such fundamental cellular processes as proliferation, differentiation, migration, chronic inflammation, and cytoskeletal organization. As a result, dysregulation of LPA content may contribute to many CNS and PNS disorders such as chronic inflammatory or neuropathic pain, glioblastoma multiforme (GBM), hemorrhagic hydrocephalus, schizophrenia, multiple sclerosis, Alzheimer’s disease, metabolic syndrome-induced brain damage, traumatic brain injury, hepatic encephalopathy-induced cerebral edema, macular edema, major depressive disorder, stress-induced psychiatric disorder, alcohol-induced brain damage, HIV-induced brain injury, pruritus, and peripheral nerve injury. ATX activity is now known to be the primary biological source of this bioactive signaling lipid, and as such, represents a potentially high-value drug target. There is currently one ATX inhibitor entering phase III clinical trials, with several additional preclinical compounds under investigation. This review discusses the physiological and pathological significance of the ATX-LPA-LPA receptor signaling axis and summarizes the evidence for targeting this pathway for the treatment of CNS diseases.

Ultrafast and Predictive Mass Spectrometry-Based Autotaxin Assays for Label-Free Potency Screening

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors

Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.

Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis

Design, Synthesis and Promising Anti-Tumor Efficacy of Novel Imidazo [1,2-A]pyridine Derivatives As Potent Autotaxin Allosteric Inhibitors

Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study

Automated MALDI Target Preparation Concept: Providing Ultra-High-Throughput Mass Spectrometry–Based Screening for Drug Discovery

Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases

Simultaneous LC–MS Analysis of Paclitaxel and Retinoic Acid in Plasma and Tissues from Tumor-Bearing Mice

Development and Validation of a Rapid and Sensitive UPLC-MS/MS Assay for Simultaneous Quantification of Paclitaxel and Cyclopamine in Mouse Whole Blood and Tissue Samples.

Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model

Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC–HR-MS

Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain

ATLAS—A High-Throughput Affinity-Based Screening Technology for Soluble Proteins: Technology Application Using P38 MAP Kinase

Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay

Hepatocyte autotaxin expression promotes liver fibrosis and cancer

A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis

'LC-electrolyte effects' improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery.

Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice

A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1